Cargando…
Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma
Metastatic melanoma remains a difficult disease to treat, and long term survivors are rare. Over the past few years, however, breakthroughs in both immunotherapy as well as targeted agents have had a tremendous impact on patients diagnosed with this disease. This review summarizes recent advances in...
Autor principal: | Salama, April K.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698188/ https://www.ncbi.nlm.nih.gov/pubmed/23843723 http://dx.doi.org/10.4137/CMO.S9565 |
Ejemplares similares
-
First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017) -
Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012) -
Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020) -
Evolving impact of long-term survival results on metastatic melanoma treatment
por: Michielin, Olivier, et al.
Publicado: (2020) -
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types
por: Gangadhar, Tara C, et al.
Publicado: (2015)